SCHEMBL950861

SCHEMBL950861

Cc1c[nH]nc1C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL19384655 0.98 NOTUM (0.40) —
Biphenyl SCHEMBL27658278 0.89 PIN1 (0.47) —
SCHEMBL15195597 0.82 — —
SCHEMBL19384586 0.80 — —
SCHEMBL169065 0.80 — —
SCHEMBL5761874 0.78 NPSR1 (0.48) —
SCHEMBL1559800 0.77 MAP4K1 (0.38) —
SCHEMBL15186359 0.77 YTHDC1 (0.42) —
SCHEMBL16209016 0.76 KDM4E (0.36) —
SCHEMBL719025 0.75 KDM4E (0.49) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12492193-B2 Pyrazole derivatives for the treatment of cystic fibrosis FONDAZIONE INSTITUTO ITALIANO DI TECNOLOGIA (IT) 2025-12-09 — — US claimed
US-20230212157-A1 PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS ISTITUTO GIANNINA GASLINI (IT) 2023-07-06 — — US claimed
US-11597723-B2 Pyrazole derivatives for the treatment of cystic fibrosis FONDAZIONE ISTITUTO ITALIANO DI TECHNOLOGIA (IT) 2023-03-07 — — US claimed
US-20150158749-A1 SELECTIVE EXTRACTION OF ANIONS FROM SOLUTION THE BOARD OF TRUSTEES OF WESTERN MICHIGAN UNIVERSITY 2015-06-11 — — US claimed
CN-101302200-B Preparation of N-piperidine subbase-5-(4-chlorphenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-formamide SHANGHAI INST PHARM INDUSTRY 2011-04-20 — — CN claimed
CN-1047775-C Substituted N-piperidino-pyrazole-3-carboxamide SANOFI SA (FR) 1999-12-29 — — CN claimed
CN-1110968-A Substituted N-piperidino-pyrazole-3-carboxamide SANOFI SA (FR) 1995-11-01 — — CN claimed
US-12492193-B2 Pyrazole derivatives for the treatment of cystic fibrosis FONDAZIONE INSTITUTO ITALIANO DI TECNOLOGIA (IT) 2025-12-09 — — US disclosed
CN-119039225-A Purification method of fluorine-containing methyl pyrazole carboxylic ester 中蓝晨光化工研究设计院有限公司 2024-11-29 — — CN disclosed
CN-118541371-A Methionine adenosyltransferase 2A inhibitors for the treatment of MTAP deleted cancers 勤浩医药(苏州)有限公司 2024-08-23 — — CN disclosed
EP-4413004-A1 MACROCYCLIC COMPOUNDS HAVING ENT1 INHIBITING ACTIVITY iTeos Belgium SA (BE) 2024-08-14 — — EP disclosed
US-20230391752-A1 PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AND RELATED USES CHULALONGKORN UNIVERSITY (TH) 2023-12-07 — — US disclosed
CN-116547275-A IL-17A modulators 赛诺菲 2023-08-04 — — CN disclosed
CN-1582278-A Polymorphous form of rimonabant, process for its preparation and pharmaceutical compositions containing it SANOFI SYNTHELABO (FR) 2005-02-16 — — CN disclosed
EP-1444210-A1 QUNAZOLINE DERIVATIVES AS ANTITUMOR AGENTS AstraZeneca AB (SE) 2004-08-11 — — EP disclosed
WO-2004058702-A2 4-[(4-(CARBOXYETHYL) PIPERIDINYL) METHYL] PYRROLIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO., INC. (US) 2004-07-15 — — WO disclosed
WO-2004058763-A1 4(SPIROPIPERIDINYL)METHYL SUBSTITUTED PYRROLIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO., INC. (US) 2004-07-15 — — WO disclosed
WO-2003040108-A1 QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS ASTRAZENECA AB (SE) 2003-05-15 — — WO disclosed
CN-1047775-C Substituted N-piperidino-pyrazole-3-carboxamide SANOFI SA (FR) 1999-12-29 — — CN disclosed
CN-1110968-A Substituted N-piperidino-pyrazole-3-carboxamide SANOFI SA (FR) 1995-11-01 — — CN disclosed
Send feedback